Jefferies Upgrades Summit Therapeutics to Buy, Raises Price Target to $25
Benzinga Newsdesk 1 month ago
NewsUpgradesAnalyst RatingsPrice Target
Jefferies analyst Faisal Khurshid upgrades Summit Therapeutics (NASDAQ:SMMT) from Hold to Buy and raises the price target from $15 to $25.
Jefferies analyst Faisal Khurshid upgrades Summit Therapeutics (NASDAQ:SMMT) from Hold to Buy and raises the price target from $15 to $25.